top of page
Share
  • LinkedIn
  • Youtube
  • X
  • Instagram
How we drive innovation
STORIES
MEETINGS
MEMBERS

Jens H. Vogel

President & COO of Mirai Bio - Former CEO of BI Fremont & Global Head of Biotech at Bayer Pharmaceuticals

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Ted Torphy

Dr. Ted Torphy brings to BioMotiv over 30 years of experience in the pharmaceutical industry with a successful record in both small-molecule and large-molecule drug discovery and preclinical development.

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Patrick Basanez

Director of GBX GROUP

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Thomas Herget

Head Silicon Valley & China Innovation Hub at Merck Group

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Behzad Mahdavi

CEO and Board Member of InnoGI Technologies

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Uwe Gottschalk

Operating Partner at Keensight Capital - Former CSO of Lonza

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Dave Malenfant

Dave Malenfant is Director, Outreach & Partnerships, Center for Supply Chain Innovation, at the Texas Christian University Neeley School of Business in Fort Worth, TX. He has more than 25 years of experience in driving change and performance

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Jesse McCool

CSO of Bionova Scientific - Former Co-Founder & CEO of Wheeler Bio

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Angela Vollstedt

Global Director, Cell & Gene Therapies Portfolio Management at Novartis

I'm an accomplished Biotech & Pharma executive with deep expertise in science, product strategy and development and commercial life-cycle management. Focusing on Advanced Therapies (CAR-T and Gene Therapy), Oncology, Immunology, and Endocrinology, I've consistently led high-performing teams to achieve groundbreaking milestones in drug development and market success.

Key achievements include:

+ Driving CMC product design and development paving the way for successful market launch and life-cycle maintenance of Zarxio™, Omnitrope™, Hyrimoz™ and Tyruko™
+ Advancing ten projects to through early clinical development into late-stage development, including four successful BLA and life-cycle maintenance product improvement approvals.

As Director, Novartis Cell & Gene Therapies R&D Portfolio, I shape key assets’ direction and secure strategic partnering and funding to achieve critical regulatory milestones. My extensive experience enables me to forge strategic partnerships and accelerate product development.

I thrive in dynamic, entrepreneurial environments, where I design and launch products that transform clinical practice and improve patient outcomes. With a passion for driving innovation, I’ve recently completed my MBA to deepen my role in shaping the technology innovation space.

My commitment to excellence is rooted in servant leadership and a steadfast belief in focusing our collective efforts to make a lasting and sustainable impact on the lives of patients around the world. I am passionate about championing the next generation of leaders as a supporter of Youth Entrepreneurship and empowering Women in Advanced Therapies and beyond.

Speakers
bottom of page